Avanos Medical, Inc. $AVNS Shares Bought by UBS Group AG

UBS Group AG grew its stake in shares of Avanos Medical, Inc. (NYSE:AVNS) by 7.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 415,107 shares of the company’s stock after acquiring an additional 30,290 shares during the quarter. UBS Group AG owned about 0.89% of Avanos Medical worth $4,662,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of AVNS. Millennium Management LLC increased its stake in shares of Avanos Medical by 312.4% during the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock valued at $10,361,000 after acquiring an additional 678,898 shares during the last quarter. Armistice Capital LLC increased its stake in shares of Avanos Medical by 22.8% during the 3rd quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock valued at $28,900,000 after acquiring an additional 464,000 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Avanos Medical by 356.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company’s stock valued at $6,834,000 after acquiring an additional 461,706 shares during the last quarter. Citadel Advisors LLC increased its position in Avanos Medical by 212.0% during the 3rd quarter. Citadel Advisors LLC now owns 574,104 shares of the company’s stock worth $6,637,000 after purchasing an additional 390,082 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Avanos Medical by 190.4% during the 2nd quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock worth $6,855,000 after purchasing an additional 367,188 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on AVNS. Wall Street Zen downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings raised shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Finally, Zacks Research downgraded shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Avanos Medical Stock Down 0.2%

AVNS opened at $24.65 on Friday. The firm has a 50 day moving average price of $19.67 and a 200 day moving average price of $15.01. The company has a market cap of $1.15 billion, a PE ratio of -15.31 and a beta of 1.58. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $24.91. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.40 and a current ratio of 2.48.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The firm had revenue of $182.20 million during the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.26 EPS. Sell-side analysts expect that Avanos Medical, Inc. will post 1.07 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.